Faculty of Life Science & Medicine, Northwest University, Xi'an, Shaanxi, China.
Department of General Practice, Xi'an International Medical Center Hospital, Xi'an, Shaanxi, China.
Pharm Biol. 2024 Dec;62(1):423-435. doi: 10.1080/13880209.2024.2351946. Epub 2024 May 17.
Diabetic kidney disease (DKD) affects nearly 40% of diabetic patients, often leading to end-stage renal disease that requires renal replacement therapies, such as dialysis and transplantation. The gut microbiota, an integral aspect of human evolution, plays a crucial role in this condition. Traditional Chinese medicine (TCM) has shown promising outcomes in ameliorating DKD by addressing the gut microbiota.
This review elucidates the modifications in gut microbiota observed in DKD and explores the impact of TCM interventions on correcting microbial dysregulation.
We searched relevant articles from databases including Web of Science, PubMed, ScienceDirect, Wiley, and Springer Nature. The following keywords were used: diabetic kidney disease, diabetic nephropathy, gut microbiota, natural product, TCM, Chinese herbal medicine, and Chinese medicinal herbs. Rigorous criteria were applied to identify high-quality studies on TCM interventions against DKD.
Dysregulation of the gut microbiota, including , , and , has been observed in individuals with DKD. Key indicators of microbial dysregulation include increased uremic solutes and decreased short-chain fatty acids. Various TCM therapies, such as formulas, tablets, granules, capsules, and decoctions, exhibit unique advantages in regulating the disordered microbiota to treat DKD.
This review highlights the importance of targeting the gut-kidney axis to regulate microbial disorders, their metabolites, and associated signaling pathways in DKD. The Qing-Re-Xiao-Zheng formula, the Shenyan Kangfu tablet, the Huangkui capsule, and the Bekhogainsam decoction are potential candidates to address the gut-kidney axis. TCM interventions offer a significant therapeutic approach by targeting microbial dysregulation in patients with DKD.
糖尿病肾病(DKD)影响近 40%的糖尿病患者,常导致需要肾脏替代治疗的终末期肾病,如透析和移植。肠道微生物群是人类进化的一个组成部分,在这种情况下起着至关重要的作用。中药(TCM)在通过解决肠道微生物群来改善 DKD 方面显示出有希望的结果。
本综述阐明了 DKD 中观察到的肠道微生物群的变化,并探讨了 TCM 干预对纠正微生物失调的影响。
我们从 Web of Science、PubMed、ScienceDirect、Wiley 和 Springer Nature 等数据库中搜索相关文章。使用了以下关键词:糖尿病肾病、糖尿病肾病、肠道微生物群、天然产物、TCM、中草药和中药。应用严格的标准来识别针对 DKD 的 TCM 干预的高质量研究。
DKD 患者存在肠道微生物群失调,包括多样性减少、厚壁菌门/拟杆菌门比例增加、共生菌减少和致病菌增加。微生物失调的关键指标包括尿毒症溶质增加和短链脂肪酸减少。各种 TCM 疗法,如方剂、片剂、颗粒、胶囊和汤剂,在调节失调的微生物群以治疗 DKD 方面具有独特的优势。
本综述强调了靶向肠-肾轴调节 DKD 中微生物紊乱、其代谢物和相关信号通路的重要性。清泻消胀正方、肾康栓片、黄葵胶囊和贝科苷散是针对肠-肾轴的潜在候选药物。TCM 干预为治疗 DKD 患者的微生物失调提供了一种重要的治疗方法。